Cardioprotection by Humoral Factors Released After Remote Ischemic Preconditioning Depends on Anesthetic Regimen

Area of Science:

• Cardiology
• Anesthesiology
• Physiology

Background:

• Remote ischemic preconditioning (RIPC) is a promising noninvasive method to mitigate ischemia-reperfusion injury.
• Clinical RIPC results are inconsistent, with propofol anesthesia suspected as an inhibitory factor.
• The mechanism by which propofol may inhibit RIPC-induced cardioprotection remains unclear.

Purpose of the Study:

• To investigate whether propofol inhibits the cardioprotective effects of RIPC.
• To determine if propofol interferes with the release of humoral factors or directly affects the myocardium.
• To elucidate the mechanism underlying propofol's potential inhibition of RIPC.

Main Methods:

• Male Wistar rats underwent RIPC via hind limb ischemia/reperfusion cycles.
• Blood plasma from RIPC or control rats, under pentobarbital or propofol anesthesia, was transferred to isolated rat hearts.
• Hearts were subjected to global ischemia and reperfusion, with infarct size determined post-treatment.

Main Results:

• RIPC plasma from pentobarbital-anesthetized rats significantly reduced infarct size in isolated hearts.
• Propofol anesthesia abolished the cardioprotective effect of RIPC plasma.
• However, RIPC plasma from pentobarbital-anesthetized rats still protected hearts perfused with propofol, indicating propofol's inhibition occurs before myocardial exposure.

Conclusions:

• Propofol anesthesia inhibits the cardioprotective effects of RIPC.
• This inhibition is attributed to propofol interfering with the release of essential humoral factors.
• Understanding this mechanism is crucial for optimizing RIPC application in clinical settings.